ECOG-ACRIN EA5191

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

Objective

This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC).

NCT#04310007

Clinical Trial Categories

• Lung Cancer

Contact

NH Oncology Hematology Clinical Research Dept. at (603) 224-2556